Core Viewpoint - China Biopharmaceutical (01177) announced the acquisition of Hejiya, a pioneer in siRNA innovative drug development, for a maximum consideration of RMB 120 million, aiming to enhance its innovation in chronic disease management and clinical advancement [1][2]. Group 1: Acquisition Details - The acquisition involves a full purchase of Hejiya's 100% equity by China Biopharmaceutical's wholly-owned subsidiary, with part of the payment in cash and part in shares [1]. - Hejiya will become an indirect wholly-owned subsidiary of China Biopharmaceutical upon completion of the transaction [1]. Group 2: Hejiya's Technology and Market Potential - Hejiya specializes in siRNA technology, addressing limitations in existing chronic disease therapies, with a projected global transaction volume in the siRNA field exceeding USD 35 billion by 2025, reflecting a growth rate of over 40% [2]. - Hejiya has developed a differentiated delivery platform with proprietary technology, including the MVIP platform for long-acting liver-targeted delivery, which addresses patient compliance issues in chronic disease treatment [3]. Group 3: Clinical Assets and Pipeline - Hejiya possesses four clinical-stage assets and over ten preclinical assets, all with first-in-class or best-in-class potential [4]. - Kylo-11, a long-acting Lp(a) siRNA, is in Phase II clinical trials, showing promising efficacy and safety for treating elevated Lp(a) levels, which affect over 1.4 billion people globally [4]. - Kylo-12, an APOC3 siRNA, aims for a biannual dosing regimen and is set to begin Phase II trials in 2026, targeting high triglyceride levels and familial chylomicronemia syndrome [5]. Group 4: Future Development Plans - Hejiya plans to advance multiple innovative projects into clinical stages by 2026, including products targeting obesity and Alzheimer's disease [6].

智通财经APP讯，中国生物制药(01177)发布公告，自2026年1月13日起：1.陈凯年先生已辞任公司秘书 及不再担任根据香港联合交易所有限公司证券上市规则第3.05条所规定公司之授权代表;及2.赖娟女士已 获委任为公司秘书及授权代表以填补该等职务。 ...

Core Viewpoint - The acquisition of Hegia Biotech by China National Pharmaceutical Group for 1.2 billion RMB marks a significant strategic move in the siRNA sector, enhancing the company's capabilities in the chronic disease treatment market and expanding its innovative drug pipeline [1][10]. Group 1: Acquisition Details - China National Pharmaceutical Group announced a full acquisition of Hegia Biotech for a total price of 1.2 billion RMB, further expanding its presence in the siRNA innovation drug sector [1]. - This acquisition follows the investment in Saintin Biotech, indicating a strategic focus on the siRNA field [1]. - The deal is expected to enhance the company's core competitiveness in the siRNA sector and open up new opportunities in the global chronic disease treatment market [1][10]. Group 2: Hegia Biotech Overview - Hegia Biotech, established in 2018, specializes in siRNA innovative products with a focus on long-acting and low-dose advantages [4]. - The core R&D team at Hegia has over 20 years of experience in siRNA drug development and holds more than 50 core patents [4]. - Hegia has developed six delivery platforms and has four innovative drugs in clinical stages, with over 20 projects in preclinical stages [4]. Group 3: Technological Advancements - Hegia's MVIP liver delivery platform is the first clinically validated siRNA platform capable of "one injection per year" [5]. - The dual-target delivery platform (DDP) allows for simultaneous delivery of dual-target siRNA, offering significant therapeutic breakthroughs [5]. - The neuro delivery platform (NSDP) aims to address unmet clinical needs in central and peripheral nervous system diseases, with products expected to enter clinical stages by 2026 [5]. Group 4: Market Potential - The global market for siRNA drugs is projected to reach $15 billion, driven by the need for effective treatments for conditions like elevated lipoprotein(a) [7]. - Hegia's Kylo-11 is the first siRNA product to achieve a 95% reduction in lipoprotein(a) levels with a single injection lasting over a year, positioning it favorably in the market [8]. - The potential market for Hegia's innovative therapies is significant, with estimates suggesting a peak sales potential of $15 billion to $21 billion for similar products [8]. Group 5: Strategic Implications - The acquisition is seen as a strategic alignment of technical capabilities and industrialization potential, enhancing Hegia's drug pipeline and accelerating market entry [10]. - The collaboration between Hegia and China National Pharmaceutical Group's existing resources is expected to foster the development of new innovative therapies [10]. - This acquisition represents a significant move in the domestic siRNA sector, marking the first major acquisition initiated by a large pharmaceutical company [10].

格隆汇1月13日丨中国生物制药(01177.HK)宣布，自2026年1月13日起：1.陈凯年已辞任公司之公司秘书 及不再担任根据香港联合交易所有限公司证券上市规则第3.05条所规定公司之授权代表；及2.赖娟已获 委任为公司之公司秘书及授权代表以填补该等职务。 ...

中國生物製藥有限公司（「本公司」）董事會（「董事會」）宣佈，自二零二六年一月十三日起： 陳先生確認與董事會並無分歧意見，亦無有關其辭任而須知會聯交所及本公司股東之事宜。 賴女士自二零二五年九月加入本公司，加入本公司之前，彼曾就職於普華永道中天會計師事務所、 里昂證券研究以及數家於聯交所上市之公司，在財務審計、資本市場、信息披露、企業管治及公司 秘書事務領域擁有逾十七年經驗。賴女士畢業於北京大學光華管理學院會計學專業，取得管理學學 士學位，並於香港大學取得工商管理碩士學位。彼為香港公司治理公會及英國特許公司治理公會特 許秘書、特許公司治理師以及會士。 1 香港交易及結算所有限公司及香港聯合交易所有限公司對本公告的內容概不負責，對其準確性或完 整性亦不發表任何聲明，並明確表示，概不對因本公告全部或任何部份內容而產生或因倚賴該等內 容而引致的任何損失承擔任何責任。 （於開曼群島註冊成立之有限公司） 網站：www.sinobiopharm.com （股份編號：1177） 公司秘書及授權代表之變更 謝其潤 香港，二零二六年一月十三日 於本公告日期，本公司董事會包括六位執行董事，即謝其潤女士、謝炳先生、鄭翔玲女士、謝承潤 ...

香港交易及結算所有限公司及香港聯合交易所有限公司對本公告的內容概不負責，對其準確性或完 整性亦不發表任何聲明，並明確表示，概不對因本公告全部或任何部份內容而產生或因倚賴該等內 容而引致的任何損失承擔任何責任。 本公告僅供參考，並不構成收購、購買或認購本公司證券的邀請或要約，亦不在任何司法權區構成 任何投票或批准的招攬。 本公告並非旨在以直接或間接方式於或向美國或有關發佈、刊發或派發屬違法的司法權區派發。本 公告並不構成在美國或任何其他倘無根據當地證券法律登記或符合資格即屬違法的司法權區，要約 提呈出售任何證券或邀請作出購買任何證券的要約。倘無登記或獲適用豁免登記規定，證券不得在 美國提呈發售或出售。於美國公開發售任何證券將須以招股章程的方式進行，而招股章程須載有關 於提呈發售的公司、管理層以及財務報表的詳盡資料。本公司無意在美國公開發售證券。 （於開曼群島註冊成立之有限公司） 網站：www.sinobiopharm.com （股份編號：1177） 股份交易 收購赫吉亞100%股權 涉及根據一般授權發行代價股份 董事會欣然宣佈，於二零二六年一月十三日，本公司（透過買方）全資收購赫吉亞。買方（本公司一 間全資附屬 ...

Group 1 - UBS report indicates that China Biologic Products (01177) management requires more time to finalize guidance on the development of its out-licensing (BD) business for this year [1] - Expected data releases this year include Phase I clinical data for TQB3702 in blood cancer, Phase II clinical data for TQA3334, and Phase III clinical data for lanifibranor targeting metabolic-associated fatty liver disease [1] - The firm maintains a "Buy" rating on the company with a target price of HKD 12.2 [1] Group 2 - Management expresses optimism regarding the inclusion prospects of VIIa in the 2025 National Medical Insurance Drug List negotiations, as only three companies were selected [1] - Penpulimab has successfully entered the medical insurance directory for the first time; anlotinib has been approved for expansion to first-line treatment of soft tissue sarcoma without any price reduction, while Yilishu benefits from an expanded reimbursement scope [1]

Group 1 - UBS reports that China Biologic Products (01177) management indicates that more time is needed to determine the guidance for the external authorization (BD) business development this year [1] - The expected data results to be announced this year include Phase I clinical data for TQB3702 in blood cancer, Phase II clinical data for TQA3334, and Phase III clinical data for lanifibranor targeting metabolic-associated fatty liver disease [1] - UBS maintains a "Buy" rating for the company with a target price of HKD 12.2 [1] Group 2 - Regarding the 2025 National Medical Insurance Drug List negotiation results, management is optimistic about the inclusion prospects for VIIa, as only three companies were selected [1] - Penpulimab has successfully entered the medical insurance directory for the first time; Anlotinib has been approved for expansion to first-line treatment of soft tissue sarcoma without any price reduction, while Yilishu benefits from an expanded reimbursement scope [1]

（文章来源：每日经济新闻） 每经AI快讯，中国生物制药(01177.HK)一度涨超4%，截至发稿涨3.5%，报7.09港元，成交额4.31亿港 元。 ...

中国生物制药（01177）盘中涨超4%，截至发稿，股价上涨3.50%，现报7.09港元，成交额4.39亿港元。 基于销售数据，美银证券微调其2026及2027年收入预测，目标价从9.4港元下调至8.3港元。此外，石药 集团因重点药品销售低迷，被维持"跑输大市"评级。 来源：新浪港股 报告显示，医院渠道销售额按年转降3.3%，零售渠道基本持平。中国生物制药产品表现分化，部分核 心产品销售额增长，但另一些显著下滑。 近日，美银证券发布报告指出，10月中国内地医药行业药品销售额按年下降3%，增速较9月大幅回落， 并重申对中国生物制药的"买入"评级。 ...